中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Dyslipidemia Management in Chinese Post Stroke Patients

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
AstraZeneca

关键词

抽象

The purpose of this study is to provide current and reliable data of dyslipidimia management together with control situation of blood pressure and glucose for post-stroke patients within 6-12 months from attack, and also the association between patient characteristics and control rate of lipids in this population.
It is an non-interventional study, no study specified treatment is required.Approximately 5000 post ischemic stroke patients within 6-12 months from attack will enter into the study. Fifty centres from different regions of China will participate in this study.

描述

This is a multicentre, cross-sectional, observational study, aiming to investigate the prevalence and control situation of dyslipidimia in China post ischemic stroke patients within 6-12 months from attack. Patients will be screened consecutively, eligible subjects will be interviewed by investigator and finish a questionire during the visit. Investigator will collect relevant medical history, physical exam results and lab test results including blood lipid (i.e. Triglyceride, Total Cholesterol, LDL-C, HDL-C) and glucose(HbA1c if available).Approximately 5000 post ischemic stroke patients within 6-12 months from attack will enter into the study. Fifty centres from different regions of China will participate in this study.

日期

最后验证: 06/30/2015
首次提交: 07/02/2013
提交的预估入学人数: 07/09/2013
首次发布: 07/11/2013
上次提交的更新: 07/28/2015
最近更新发布: 07/29/2015
实际学习开始日期: 06/30/2013
预计主要完成日期: 07/31/2014
预计完成日期: 07/31/2014

状况或疾病

Brain Ischemia,Stoke

-

手臂组

干预/治疗
One Group
Full Analysis Set (FAS) will be the primary analysis set. All post ischemic stroke patients within 6-12 months from attack (i.e., with inclusion criterion No.2 fulfilled) except the screening failure patients, i.e., those who withdraw from the study once the informed consent is given, will be included in the FAS.

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
取样方式Non-Probability Sample
接受健康志愿者
标准

Inclusion Criteria:

1. Male or female with age ≥ 18 years

2. Post ischemic stroke patients within 6-12 months from attack

3. written informed consent is provided to participant in the study

Exclusion Criteria:

1. Significant medical or psychological condition that make patients can not finish the questionnaire independently or with the aids of his/her legal representatives

2. The patient is or will be in another clinical study

3. Previous enrolment in the present study

结果

主要结果指标

1. To observe LDL-C level of China post-stroke patients within 6-12 months from attack [Up to 12 months]

Investigator will collect lab test results including blood lipid (i.e. Triglyceride, Total Cholesterol, LDL-C, HDL-C) during the patient visit.

2. To observe control rate of LDL-C of China post-stroke patients within 6-12 months from attack [Up to 12 months]

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge